FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2104893459> ?p ?o ?g. }

• W2104893459 endingPage "575" @default.
• W2104893459 startingPage "567" @default.
• W2104893459 abstract "The pharmacokinetics of cefotaxime, moxalactam, and ceftazidime were investigated in six human volunteers who received in a crossover fashion doses of 0.5, 1.0, and 2.0 g of each drug by a 5-min infusion. Doses of 1.0 g were repeated after the administration of probenecid. Serum and urine concentrations were assayed with an agar diffusion method. Serum concentrations of moxalactam exceeded those of ceftazidime at all times and were distinctly higher than those of cefotaxime. The normalized area under the concentration time curve (defined as the ratio of the area under the curve per dose) reflects this relationship: compared with cefotaxime the normalized area under the curve of moxalactam was 3 to 4 times higher, and that of ceftazidime was 2 to 3 times higher. By intra-individual comparisons, the area under the curve of moxalactam was 44% larger than that of ceftazidime. With increasing doses, cefotaxime exhibited a nonlinear increase of the area under the curve. The half-lives of moxalactam, ceftazidime, and cefotaxime were 2.34, 1.95, and 1.16 h, respectively. The volume of distribution averaged 0.20 ± 0.03, 0.23 ± 0.02, and 0.25 ± 0.04 liters per kg, and the mean total body clearance was 84, 131, and 328 ml/min for moxalactam, ceftazidime, and cefotaxime, respectively. The 24-h urinary recovery was highest for moxalactam (75 ± 4%) followed by ceftazidime (68 ± 11%) and cefotaxime (53 ± 6%). The influence of probenecid on serum concentrations, half-life, area under the curve, and clearance was most apparent with cefotaxime, whereas the pharmacokinetics of moxalactam and ceftazidime were only slightly affected. After the 0.5− and 2.0− g doses of cefotaxime, desacetyl-cefotaxime activity (determined by high-pressure liquid chromatography) reached a peak of 2.7 and 9.9 μg/ml and declined with a half-life of 1.9 and 1.4 h. The ratio of the R(−) and S(−) epimers of moxalactam, which could be differentiated by high-pressure liquid chromatography, fell rapidly from 0.81 at 0.17 h to 0.5 at 5 h, indicating the presence of twice as much of the microbiologically less active S(−) epimer. From a pharmacokinetic standpoint it appears reasonable to conclude that moxalactam and possibly ceftazidime could be administered twice daily and that cefotaxime could be administered three or even four times daily." @default.
• W2104893459 created "2016-06-24" @default.
• W2104893459 creator A5007036912 @default.
• W2104893459 creator A5010875182 @default.
• W2104893459 creator A5035047751 @default.
• W2104893459 creator A5062602190 @default.
• W2104893459 creator A5081752431 @default.
• W2104893459 creator A5085884218 @default.
• W2104893459 date "1981-11-01" @default.
• W2104893459 modified "2023-10-10" @default.
• W2104893459 title "Comparative Multiple-Dose Pharmacokinetics of Cefotaxime, Moxalactam, and Ceftazidime" @default.
• W2104893459 cites W1577105332 @default.
• W2104893459 cites W1978360072 @default.
• W2104893459 cites W1983295846 @default.
• W2104893459 cites W1999915326 @default.
• W2104893459 cites W2004740302 @default.
• W2104893459 cites W2007369804 @default.
• W2104893459 cites W2013168532 @default.
• W2104893459 cites W2036156550 @default.
• W2104893459 cites W2043013401 @default.
• W2104893459 cites W2043723619 @default.
• W2104893459 cites W2058228223 @default.
• W2104893459 cites W2075358437 @default.
• W2104893459 cites W2077039014 @default.
• W2104893459 cites W2085642358 @default.
• W2104893459 cites W2129844010 @default.
• W2104893459 doi "https://doi.org/10.1128/aac.20.5.567" @default.
• W2104893459 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/181752" @default.
• W2104893459 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6275776" @default.
• W2104893459 hasPublicationYear "1981" @default.
• W2104893459 type Work @default.
• W2104893459 sameAs 2104893459 @default.
• W2104893459 citedByCount "85" @default.
• W2104893459 countsByYear W21048934592017 @default.
• W2104893459 countsByYear W21048934592018 @default.
• W2104893459 countsByYear W21048934592020 @default.
• W2104893459 countsByYear W21048934592022 @default.
• W2104893459 crossrefType "journal-article" @default.
• W2104893459 hasAuthorship W2104893459A5007036912 @default.
• W2104893459 hasAuthorship W2104893459A5010875182 @default.
• W2104893459 hasAuthorship W2104893459A5035047751 @default.
• W2104893459 hasAuthorship W2104893459A5062602190 @default.
• W2104893459 hasAuthorship W2104893459A5081752431 @default.
• W2104893459 hasAuthorship W2104893459A5085884218 @default.
• W2104893459 hasBestOaLocation W21048934592 @default.
• W2104893459 hasConcept C112705442 @default.
• W2104893459 hasConcept C126322002 @default.
• W2104893459 hasConcept C185592680 @default.
• W2104893459 hasConcept C2776769776 @default.
• W2104893459 hasConcept C2776968632 @default.
• W2104893459 hasConcept C2777637488 @default.
• W2104893459 hasConcept C2778719061 @default.
• W2104893459 hasConcept C2780026642 @default.
• W2104893459 hasConcept C2909971615 @default.
• W2104893459 hasConcept C501593827 @default.
• W2104893459 hasConcept C523546767 @default.
• W2104893459 hasConcept C54355233 @default.
• W2104893459 hasConcept C55493867 @default.
• W2104893459 hasConcept C64778159 @default.
• W2104893459 hasConcept C71924100 @default.
• W2104893459 hasConcept C76318530 @default.
• W2104893459 hasConcept C86803240 @default.
• W2104893459 hasConcept C98274493 @default.
• W2104893459 hasConceptScore W2104893459C112705442 @default.
• W2104893459 hasConceptScore W2104893459C126322002 @default.
• W2104893459 hasConceptScore W2104893459C185592680 @default.
• W2104893459 hasConceptScore W2104893459C2776769776 @default.
• W2104893459 hasConceptScore W2104893459C2776968632 @default.
• W2104893459 hasConceptScore W2104893459C2777637488 @default.
• W2104893459 hasConceptScore W2104893459C2778719061 @default.
• W2104893459 hasConceptScore W2104893459C2780026642 @default.
• W2104893459 hasConceptScore W2104893459C2909971615 @default.
• W2104893459 hasConceptScore W2104893459C501593827 @default.
• W2104893459 hasConceptScore W2104893459C523546767 @default.
• W2104893459 hasConceptScore W2104893459C54355233 @default.
• W2104893459 hasConceptScore W2104893459C55493867 @default.
• W2104893459 hasConceptScore W2104893459C64778159 @default.
• W2104893459 hasConceptScore W2104893459C71924100 @default.
• W2104893459 hasConceptScore W2104893459C76318530 @default.
• W2104893459 hasConceptScore W2104893459C86803240 @default.
• W2104893459 hasConceptScore W2104893459C98274493 @default.
• W2104893459 hasIssue "5" @default.
• W2104893459 hasLocation W21048934591 @default.
• W2104893459 hasLocation W21048934592 @default.
• W2104893459 hasLocation W21048934593 @default.
• W2104893459 hasLocation W21048934594 @default.
• W2104893459 hasLocation W21048934595 @default.
• W2104893459 hasOpenAccess W2104893459 @default.
• W2104893459 hasPrimaryLocation W21048934591 @default.
• W2104893459 hasRelatedWork W1979805305 @default.
• W2104893459 hasRelatedWork W1986089732 @default.
• W2104893459 hasRelatedWork W2004740302 @default.
• W2104893459 hasRelatedWork W2104893459 @default.
• W2104893459 hasRelatedWork W2112873084 @default.
• W2104893459 hasRelatedWork W2351680346 @default.
• W2104893459 hasRelatedWork W2400903057 @default.
• W2104893459 hasRelatedWork W2465833206 @default.
• W2104893459 hasRelatedWork W4255296578 @default.

• next